4130 Share Price Performance
Recent 4130 News & Updates
No updates
Genovate Biotechnology Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.17
- Gross Margin
- 36.57%
- Net Profit Margin
- 3.70%
- Debt/Equity Ratio
- 0%
Genovate Biotechnology Co., Ltd. Competitors
About 4130
- Founded
- 1982
- Employees
- 191
- CEO
- WebsiteView website
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. The company was founded in 1982 and is based in Hsinchu City, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.3%
- 3 Months: 12.3%
- 1 Year: 6.6%
- Year to Date: 2.0%
The Energy sector gained 7.6% while the market remained flat over the last week. As for the longer term, the market has risen 6.6% in the past 12 months. Earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading